Navigation Links
Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of,Blindness in Premature Infants

RICHMOND, Va.--(BUSINESS WIRE)--Jun 26, 2007 - Insmed Incorporated (Nasdaq:INSM), a biopharmaceutical company focused on the development and approval of drugs for the treatment of metabolic diseases with unmet medical needs, today noted the publication of promising results of research from three universities regarding the potential role of insulin-like growth factor binding protein-3 (IGFBP-3) in the prevention of blindness among premature infants.

IGFBP-3 is a key component of Insmed's lead drug candidate, IPLEX(TM), which has been approved by the U.S. Food and Drug Administration for the treatment of a severe growth disorder and is currently being studied as a treatment for myotonic muscular dystrophy, HIV-associated adipose redistribution syndrome and retinopathy of prematurity (ROP). IPLEX(TM) is the combination of IGFBP-3 with recombinant human insulin-like growth factor 1 (IGF-I).

The new study results, published in the June 19 issue of the Proceedings of the National Academy of Sciences, focus on the action of IGFBP-3 in promoting normal tissue growth and preventing ROP. Researchers at the University of Florida reported that mice treated with IGFBP-3 showed closer-to-normal growth of retinal vasculature than mice without IGFBP-3 in similar high-oxygen conditions. Researchers at Harvard Medical School and the University of Goteborg in Sweden reported similar results.

In addition, Harvard Medical School researchers, in collaboration with researchers at the University of Goteborg, reported results of a clinical study showing IGFBP-3 levels in infants with ROP were lower than those of healthy babies. The researchers said these results suggest that IGFBP-3, acting independently of IGF-I, helps prevent oxygen-induced loss of blood-vessels and helps promote vascular re-growth.

Insmed Chairman and CEO Geoffrey Allan, Ph.D., commented: "These studies by researchers at three distinguished univ
'"/>




Page: 1 2 3

Related medicine technology :

1. Insmed Inc. to Present at C.E. Unterberg, Towbin Growth Conference
2. Insmed Announces Promising Results From IPLEX Phase II Myotonic Muscular Dystrophy Clinical Study
3. Insmed Releases Positive Results from Iplex Phase II HIV-Associated Adipose Redistribution Syndrome Clinical Study
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
6. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
7. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
8. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
9. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
10. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
11. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
Post Your Comments:
(Date:4/27/2015)... MILAN , April 27, 2015  USL di ... Italian province of Reggio Emilia, has implemented Zebra ... throughout the hospital. The Wireless Network Solution ... patients, medical records securely and in real time via ... available at all times. Zebra also provides employee and ...
(Date:4/27/2015)... SAN DIEGO , April 27, 2015  Agena Bioscience ... (CSP) for Agena Bioscience,s MassARRAY platform in China ... at unprecedented speed. It is a hotbed for practical, meaningful ... China and for the rest of the world. ... community in China ," said Peter ...
(Date:4/27/2015)... -- China Jo-Jo Drugstores, Inc. (NASDAQ CM: ... leading China-based retail and wholesale distributor that offers pharmaceutical ... pharmacies, today announced its subsidiary, Hangzhou Jiuzhou Grand Pharmacy ... sales incentive agreement with Wyeth Pharmaceutical Company, Ltd. ("Wyeth"), ... of Pfizer Inc. (NYSE: PFE ) (the ...
Breaking Medicine Technology:Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 2Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 3Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 4Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 5Agena Bioscience Names Bioyong Technology as Fifth Certified Service Provider in China 2China Jo-Jo Drugstore Signed a New Sales Incentive Agreement with Wyeth Pharmaceutical, a Subsidiary of Pfizer 2China Jo-Jo Drugstore Signed a New Sales Incentive Agreement with Wyeth Pharmaceutical, a Subsidiary of Pfizer 3China Jo-Jo Drugstore Signed a New Sales Incentive Agreement with Wyeth Pharmaceutical, a Subsidiary of Pfizer 4
... Disease Week ... 2008, ... today that it has initiated the Phase 2 clinical,development program of MDX-1100, ... ulcerative colitis (UC) and,rheumatoid arthritis (RA). MDX-1100 could potentially treat UC and ...
... Thailand, May 9 An emergency,veterinary team from the ... stand-by in Thailand awaiting authority to enter cyclone struck,Myanmar ... of animals,that human survivors depend on for food and ... The Food and Agriculture,Organization of the United Nations (FAO) ...
Cached Medicine Technology:Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis 2Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis 3Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis 4Animals That Cyclone Survivors Depend on Need Help Now 2
(Date:4/27/2015)... On April 16, 2015, Harper’s Bazaar Magazine, in ... Marks ,” interviewed a UK dermatologist on the causes and ... are a type of scar that reportedly affects nearly 90% ... of the elsastin and collagen in the dermis, the dense ... mark removal with the Coolbeam protocol is one of our ...
(Date:4/27/2015)... 2015 Beckman Coulter is sponsoring a ... study the evolution of neural circuitry and swimming behavior ... the mechanisms by which analogous forms of swimming behavior, ... evolved independently in certain sea slug clades. The webinar ... April 30, 2015 at 8:00am PT. , Sea slugs ...
(Date:4/27/2015)... Humble, TX (PRWEB) April 27, 2015 Sitting ... legs to ache and feel tired, and for those whose ... such as receptionists and taxi cab drivers, or to be ... teachers and hairdressers, the discomfort can be more severe and ... tired, achy leg syndrome. Dr. Madaiah Revana of Northeast Houston ...
(Date:4/27/2015)... PA (PRWEB) April 27, 2015 FMC ... will exhibit its wide range of market leading ingredients ... May 7 in Geneva, Switzerland. Vitafoods Europe 2015 expects ... 100 countries showcasing the latest research in such areas ... nutrition. , FMC Health and Nutrition’s booth will ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 Telematics Berlin ... tier 1&2 suppliers, associations, CE players and the government ... has opened to the car. This year’s panel on ... DG-Move at the European Commission, is an opportunity to ... and define a European Automotive Security Standard for years ...
Breaking Medicine News(10 mins):Health News:Stretch Marks: The Latest Treatment Options for Stretch Mark Removal 2Health News:Beckman Coulter Genomics Presents Using Next-Gen Sequencing to Study the Evolution of Neural Circuitry 2Health News:Beckman Coulter Genomics Presents Using Next-Gen Sequencing to Study the Evolution of Neural Circuitry 3Health News:Northeast Houston Vein Center Offers Tips on How to Treat Achy Legs 2Health News:Northeast Houston Vein Center Offers Tips on How to Treat Achy Legs 3Health News:FMC Health and Nutrition to Feature Epax® Brand Omega-3 Ingredients at Vitafoods Europe 2015 2Health News:Telematics Berlin: European Commission discuss a pan European Automotive Security Strategy 2Health News:Telematics Berlin: European Commission discuss a pan European Automotive Security Strategy 3
... 25 Smart Balance Inc.,(Nasdaq: SMBL ) will ... on Wednesday, May 21, 2008, at the Teaneck Marriott ... 07666. Stockholders of record,at the close of business on ... all matters that properly come before the meeting., ...
... passed the Genetic Information Nondiscrimination Act (GINA) on April 24, ... which passed the House April 25, 2007 by a vote ... measure again quickly before sending it to President Bush to ... wait, Americans can now be confident that their genetic information ...
... A Johns Hopkins University biologist, in research with implications ... has determined that the eye uses light to reset ... ability to see. , The findings suggest that patients ... can be linked to lack of exposure to daylight ...
... InfoLogix, Inc.,(Nasdaq: IFLG ), a leading technology ... commercial industries, will release its,financial results for the ... 30th, 2008. Following the press release, President and ... Jay Roberts will,host a conference call with the ...
... had less blood loss, shorter hospital stays, study finds ... laparoscopic surgery to remove pancreatic tumors or cysts leads ... study finds. , In laparoscopic surgery, doctors make ... progress with fiber optics and video cameras. This less ...
... (OTC Bulletin,Board: NTRZ), a world leader in stabilized ... that it has entered into,definitive agreements to sell ... of $20,000,000. The offering is made,pursuant to the ... by,NutraCea with the Securities and Exchange Commission (the ...
Cached Medicine News:Health News:Genetic Information Nondiscrimination Act clears Senate 2Health News:Different processes govern sight, light detection 2Health News:InfoLogix to Report First Quarter Results on April 30, 2008 2Health News:Laparoscopic Surgery on Pancreas Has Fewer Complications 2Health News:NutraCea Announces $20 Million Securities Offering 2Health News:NutraCea Announces $20 Million Securities Offering 3
Inquire...
Inquire...
Inquire...
The modular, high-end stereomicroscope; meets even the most critical demands in research and quality control provides high-contrast images with excellent depth of field and color fidelity...
Medicine Products: